ORHub purchased 100% of the equity interest and assets of PUR Biologics.
ORHub will enter the global medical device market using PUR's proprietary technologies to regenerate cartilage, mitigate pain and address the biological causes of degenerative disc disease and joint osteoarthritis.
ORHub is a SaaS-based healthcare data analytics company focused on the business of surgery to improve the profitability of health systems, hospitals and ambulatory surgery centers.
PUR Biologics has a complete line of synthetic biologics currently cleared by FDA, and its development pipeline includes two technologies that work together to provide new solutions for regenerative medicine.
"We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PUR's can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our body's natural healing capabilities," said CJ Wiggins, Founder, Executive Chairman, President & CEO for ORHub.
"PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market," said Ryan Fernan, former CEO of PUR Biologics.